M 1001Alternative Names: M-1001; MEDICA M1001
Latest Information Update: 25 Jul 2016
At a glance
- Originator SyndromeX
- Class Antihyperlipidaemics
- Mechanism of Action AMP activated protein kinase modulators; FOXO1 protein expression modulators; Hepatocyte nuclear factor 4 modulators; Mitochondrial permeability transition pore modulators; STAT3 transcription factor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dyslipidaemias
Most Recent Events
- 25 Jul 2016 Phase-II clinical trials in Dyslipidaemias in Israel (PO)